Last reviewed 2026-05-14 · How we verify

Single IV dose of GSK2862277

GlaxoSmithKline · Phase 1 active Small molecule

Single IV dose of GSK2862277 is a Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 1 development.

At a glance

Generic name	Single IV dose of GSK2862277
Sponsor	GlaxoSmithKline
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Investigate the Safety Tolerability Pharmacokinetics, and Pharmacodynamics of Inhaled and Intravenous GSK2862277 in Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Single IV dose of GSK2862277 CI brief — competitive landscape report
Single IV dose of GSK2862277 updates RSS · CI watch RSS
GlaxoSmithKline portfolio CI

Frequently asked questions about Single IV dose of GSK2862277

What is Single IV dose of GSK2862277?

Single IV dose of GSK2862277 is a Small molecule drug developed by GlaxoSmithKline.

Who makes Single IV dose of GSK2862277?

Single IV dose of GSK2862277 is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What development phase is Single IV dose of GSK2862277 in?

Single IV dose of GSK2862277 is in Phase 1.

Manufacturer: GlaxoSmithKline — full pipeline
Compare: Single IV dose of GSK2862277 vs similar drugs
Pricing: Single IV dose of GSK2862277 cost, discount & access